ACF’s European Manifesto: Addressing Critical Gaps in Research and Treatment of Rare Cancers🎗️

The Anticancer Fund (ACF) has launched its European Manifesto 2024, presenting a forward-looking strategy to position Europe as a global leader in cancer treatment innovation. With cancer rates set to rise dramatically—35 million new cases projected by 2050—there’s no time to waste. 🕒

SPAGN fully supports the goals set out by the ACF in its Manifesto, with a focus on rare cancers such as sarcomas.

🎯 Addressing Critical Gaps in Cancer Treatment

Despite breakthroughs in treatments like immunotherapies, rare cancers incl. pediatric cancers continue to be underserved. The ACF manifesto urges innovation through drug repurposing and clinical trial platforms that benefit all patients, incl. those with rare cancers.

💊 What’s Next? A Call for Research Beyond Commercial Interests

ACF champions research that isn’t driven solely by financial gain. Article 48 of the proposed EU Pharmaceutical Regulation is crucial to this mission, enabling non-profit research to bring repurposed drugs to market. This would particularly benefit cancers that are currently neglected.

🏥 Building Better Clinical Trial Infrastructure

Public clinical trial platforms, accessible across Europe, would ensure that the best treatments reach patients faster. Joint scientific reviews from the EMA and HTA would further streamline this process, cutting through red tape and improving patient outcomes. 🚀

🗣️ What Can You Do?

ACF calls on policymakers and advocates to:

• Support innovative funding models that unite public and private sectors.
• Ensure that Article 48 is adopted, allowing non-profit entities to lead in drug repurposing.

This bold vision could change the landscape of cancer care in Europe. For more details and to take action, visit anticancerfund.org or read the entire Manifesto here.